SR9011

SR9011
Identifiers

IUPAC name 3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)-N-pentylpyrrolidine-1-carboxamide
CAS Number	1379686-29-9
PubChem CID	57394021
ChemSpider	28487552
ChEMBL	CHEMBL1961797
Chemical and physical data
Formula	C₂₃H₃₁ClN₄O₃S
Molar mass	479.03524 g/mol
3D model (JSmol)	Interactive image
SMILES CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc3ccc(s3)[N+](=O)[O-])C1
InChI InChI=1S/C23H31ClN4O3S/c1-2-3-4-12-25-23(29)27-13-11-19(16-27)15-26(14-18-5-7-20(24)8-6-18)17-21-9-10-22(32-21)28(30)31/h5-10,19H,2-4,11-17H2,1H3,(H,25,29) Key:PPUYOYQTTWJTIU-UHFFFAOYSA-N

SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC₅₀) = 790 nM for Rev-Erbα and IC₅₀ = 560 nM for Rev-ErbAβ.^[1]

References

↑ Solt LA; Wang Y; Banerjee S; Hughes T; Kojetin DJ; Lundasen T; Shin Y; Liu J; Cameron MD; Noel R; Yoo SH; Takahashi JS; Butler AA; Kamenecka TM; Burris TP (May 2012). "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature. 485 (7396): 62–8. PMC 3343186 . PMID 22460951. doi:10.1038/nature11030. Lay summary – Nature Magazine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

SR9011

See also

References